Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434822 | 0.95 | EPHX1 (0.38) | EPHX1HPGDKMT2AACHEMAPK1 | |
| SCHEMBL17059026 | 0.80 | LIPA (0.32) | KMT2AP2RX7 | |
| SCHEMBL13093773 | 0.80 | LIPA (0.32) | KMT2AP2RX7 | |
| SCHEMBL5012650 | 0.79 | CES2 (0.48) | EPHX1HPGDKMT2AEPHX2ALDH1A1 | |
| SCHEMBL8932335 | 0.79 | ACHE (0.48) | EPHX1KMT2AACHEMAPT | |
| SCHEMBL8932333 | 0.79 | ACHE (0.48) | EPHX1KMT2AACHEMAPT | |
| SCHEMBL8932334 | 0.79 | ACHE (0.48) | EPHX1KMT2AACHEMAPT | |
| Ammonia Solution, Strong SCHEMBL688467 | 0.77 | ACHE (0.46) | EPHX1ACHE | |
| SCHEMBL9187411 | 0.77 | — | — | |
| Ammonia Solution, Strong SCHEMBL689387 | 0.74 | ACHE (0.43) | EPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883952-B2 | Optically anisotropic compound and resin composition comprising the same | LG CHEM, LTD. (KR) | 2014-11-11 | — | — | US | disclosed |
| US-8163359-B2 | Retardation film, and polarizing plate and liquid crystal display comprising the same | LG CHEM, LTD. (KR) | 2012-04-24 | — | — | US | disclosed |
| US-20100105816-A1 | OPTICALLY ANISOTROPIC COMPOUND AND RESIN COMPOSITION COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20090169774-A1 | Retardation film, and polarizing plate and liquid crystal display comprising the same | LG CHEM, LTD. (KR) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105816-A1 | OPTICALLY ANISOTROPIC COMPOUND AND RESIN COMPOSITION COMPRISING THE SAME | RER1, SEM1, RCC1 | EPHX1 926/4885HPGD 3795/4885KMT2A 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.